Total Payments
$743.85
2024 Payments
$209.71
Companies
20
Transactions
43
Medicare Patients
7,744
Medicare Billing
$4.5M
Payment Breakdown by Category
Food & Beverage$673.89 (90.6%)
Education$69.96 (9.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $673.89 | 37 | 90.6% |
| Education | $69.96 | 6 | 9.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.45 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $86.65 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $70.02 | 3 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $55.68 | 3 | $0 (2023) |
| PFIZER INC. | $49.28 | 4 | $0 (2023) |
| Mirati Therapeutics, Inc. | $41.13 | 2 | $0 (2024) |
| Seattle Genetics, Inc. | $36.87 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $34.92 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $33.73 | 2 | $0 (2024) |
| Amgen Inc. | $30.47 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $209.71 | 10 | E.R. Squibb & Sons, L.L.C. ($46.64) |
| 2023 | $202.82 | 10 | Janssen Biotech, Inc. ($50.25) |
| 2022 | $162.17 | 8 | E.R. Squibb & Sons, L.L.C. ($36.11) |
| 2021 | $22.97 | 2 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $24.19 | 2 | Seattle Genetics, Inc. ($12.29) |
| 2018 | $43.10 | 4 | Seattle Genetics, Inc. ($24.58) |
| 2017 | $78.89 | 7 | PFIZER INC. ($33.31) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.90 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.11 | General |
| 07/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.35 | General |
| Category: Oncology | ||||||
| 05/15/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Oncology | ||||||
| 01/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.29 | General |
| Category: Oncology | ||||||
| 11/13/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Oncology | ||||||
| 07/31/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Oncology | ||||||
| 06/29/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Oncology | ||||||
| 04/24/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.65 | General |
| Category: Oncology | ||||||
| 03/06/2023 | Incyte Corporation | PEMAZYRE (Drug), JAKAFI, MONJUVI | Food and Beverage | Cash or cash equivalent | $13.37 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 03/02/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: Oncology | ||||||
| 02/13/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: ONCOLOGY | ||||||
| 01/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 10/03/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.76 | General |
| 08/25/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.35 | General |
| Category: Oncology | ||||||
| 07/06/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,657 | 47,177 | $2.1M | $730,691 |
| 2022 | 41 | 1,725 | 67,219 | $2.6M | $1.1M |
| 2021 | 52 | 2,134 | 78,093 | $3.2M | $1.3M |
| 2020 | 54 | 2,228 | 93,045 | $3.6M | $1.4M |
Total Patients
7,744
Total Services
285,534
Medicare Billing
$4.5M
Procedure Codes
187
All Medicare Procedures & Services
187 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 7,200 | $655,200 | $311,291 | 47.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 20 | 3,000 | $285,000 | $107,021 | 37.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 5,700 | $142,500 | $105,120 | 73.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 169 | 400 | $80,000 | $36,873 | 46.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 132 | 349 | $137,855 | $34,584 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 324 | 495 | $74,250 | $30,615 | 41.2% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 14 | 324 | $226,800 | $29,026 | 12.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 41 | 23,460 | $46,920 | $9,082 | 19.4% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 16 | 23 | $18,975 | $7,647 | 40.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 104 | $14,040 | $6,284 | 44.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 41 | $11,275 | $5,725 | 50.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 77 | 113 | $16,950 | $5,596 | 33.0% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 14 | 1,715 | $154,350 | $5,564 | 3.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 89 | $14,240 | $5,016 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $12,200 | $4,799 | 39.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 77 | 300 | $15,000 | $3,591 | 23.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 56 | $10,080 | $2,823 | 28.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $6,630 | $2,527 | 38.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 40 | 118 | $11,210 | $2,472 | 22.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 166 | $9,130 | $1,759 | 19.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 67 | $5,695 | $1,691 | 29.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 38 | $2,850 | $1,464 | 51.4% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 14 | 22 | $4,400 | $1,445 | 32.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 28 | 89 | $3,738 | $1,429 | 38.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 12 | $2,400 | $1,110 | 46.3% |
About Dr. Sharon Goble, M.D
Dr. Sharon Goble, M.D is a Hematology & Oncology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255394417.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sharon Goble, M.D has received a total of $743.85 in payments from pharmaceutical and medical device companies, with $209.71 received in 2024. These payments were reported across 43 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($673.89).
As a Medicare-enrolled provider, Goble has provided services to 7,744 Medicare beneficiaries, totaling 285,534 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 187 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Richmond, VA
- Active Since 04/10/2006
- Last Updated 05/21/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1255394417
Products in Payments
- IMBRUVICA (Drug) $108.83
- OPDIVO (Biological) $83.69
- KRAZATI (Drug) $41.13
- ADCETRIS (Biological) $36.87
- KEYTRUDA (Biological) $33.73
- LUTATHERA (Drug) $29.98
- INLYTA (Drug) $26.86
- Lenvima (Drug) $26.32
- XPOVIO (Drug) $24.57
- KISQALI (Drug) $23.86
- TAGRISSO (Drug) $22.14
- DARZALEX (Biological) $21.60
- EPKINLY (Drug) $21.44
- LUMAKRAS (Drug) $19.37
- PLUVICTO (Drug) $16.18
- SANCUSO (Drug) $13.40
- PEMAZYRE (Drug) $13.37
- IMFINZI (Drug) $12.78
- Erleada (Drug) $11.90
- SUTENT (Drug) $11.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Richmond
Dr. Victor Yazbeck, M.d, M.D
Hematology & Oncology — Payments: $390,374
Hematology & Oncology $390,374
Attique Samdani, M.d, M.D
Hematology & Oncology — Payments: $146,382
Hematology & Oncology $146,382
Dr. Elke Friedman, Md, MD
Hematology & Oncology — Payments: $25,274
Hematology & Oncology $25,274
Dr. Asit Paul, M.d., Ph.d.,, M.D., PH.D.,
Hematology & Oncology — Payments: $7,490
Hematology & Oncology $7,490
Dr. Ghulam Qureshi, M.d, M.D
Hematology & Oncology — Payments: $7,032
Hematology & Oncology $7,032
Gisa-Beate Schunn, M.d, M.D
Hematology & Oncology — Payments: $5,929
Hematology & Oncology $5,929